How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/remifentanil-lidocaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Remifentanil+Lidocaine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remifentanil+Lidocaine (Remifentanil+Lidocaine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic + Local anesthetic combination. Area: Anesthesia, Pain Management.

marketed Opioid analgesic + Local anesthetic combination Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine) Anesthesia, Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Remifentanil+Lidocaine (Remifentanil+Lidocaine) — The First Affiliated Hospital of Zhengzhou University. Remifentanil is an opioid agonist that binds mu receptors to provide analgesia and sedation, while lidocaine is a local anesthetic that blocks sodium channels to provide local pain relief.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Remifentanil+Lidocaine TARGET	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Remifentanil + Lidocaïne	Remifentanil + Lidocaïne	University Hospital, Montpellier	phase 3	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic + Local anesthetic combination class)

The First Affiliated Hospital of Zhengzhou University · 1 drug in this class
University Hospital, Montpellier · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Remifentanil+Lidocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/remifentanil-lidocaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab